Drug Trial Radar · NCT00936390
Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer
Last checked: Nov 19, 2026Latest source record: Mar 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,538
Actual
Start
Sep 2009
Primary completion
Oct 3, 2020
Study completion Sep 4, 2025
Sponsor
- Lead sponsor
- Radiation Therapy Oncology GroupResearch network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI); NRG Oncology
- First posted
- Jul 10, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells and shrink tumors. Androgens can cause the growth of prostate cancer cells. Androgen-deprivation therapy may lessen the amount of androgens made by the body. It is not yet known whether radiation therapy is more effective with or without androgen-deprivation therapy in treating patients with prostate cancer. PURPOSE: This randomized phase III trial is studying radiation therapy to see how well it works compared with radiation therapy given together with androgen-deprivation therapy in treating patients with prostate cancer.
Conditions
- Prostate Cancer
Interventions
bicalutamideDrug
Administered orally at a dose of one 50 mg tablet per day, beginning within (before, same day as, or after) 10 days of the date of the first LHRH agonist (antagonist) therapy administration and continuing for a total duration of 6 months.
flutamideDrug
Administered orally at a dose of 250 mg (two 125-mg capsules) three times a day for a total daily dose of 750 mg, beginning within (before, same day as, or after) 10 days of with the date of the first LHRH agonist (antagonist) therapy administration and continuing for a total duration of 6 months.
LHRH agonist (antagonist) therapyDrug
LHRH agonist (antagonist) therapy consists of leuprolide, goserelin, buserelin, triptorelin, or degarelix. The manufacturer's instructions should be followed. The first administration occurs with the start of anti-androgen treatment 8 weeks prior to the start of RT. The total duration of LHRH agonist (antagonist) therapy is 6 months.
Dose-Escalated Radiation TherapyRadiation
External beam radiotherapy (EBRT) as 3D Conformal Radiotherapy (3DCRT) or intensity-modulated radiation therapy (IMRT). Brachytherapy is optional, at the discretion of the treating physician. Patients treated entirely via EBRT receive 79.2 Gy delivered in 1.8 Gy fractions. Patients who receive brachytherapy as a component of their RT receive 45 Gy EBRT in 1.8 Gy fractions. Low-dose brachytherapy boost occurs following the EBRT portion of treatment no more than 4 weeks following its completion.High-dose rate brachytherapy boost is delivered in 2 fractions separated by a minimum time span of 6 hours and the implant(s) may be performed during the EBRT portion of the treatment or within 1 week prior to its initiation or following its completion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Alive (Overall Survival)Time frame: From randomization to last follow-up. Follow-up schedule: end of RT (2nd arm only), then every 3 months for a year, every 4 months for 4 years, then yearly. Maximum follow-up at time of analysis was 10.3 years. Five-year rates reported here.
Locations
518 sites in 2 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama
Fairbanks Memorial Hospital
Fairbanks, Alaska
Arizona Center for Cancer Care-Peoria
Peoria, Arizona
Saint Joseph's Hospital and Medical Center
Phoenix, Arizona
21st Century Oncology-Scottsdale
Scottsdale, Arizona
Mayo Clinic in Arizona
Scottsdale, Arizona
Arizona Oncology Services Foundation
Scottsdale, Arizona
Arizona Oncology Associates-West Orange Grove
Tucson, Arizona
Mercy Cancer Center-Hot Springs
Hot Springs, Arkansas
Sutter Cancer Centers Radiation Oncology Services-Auburn
Auburn, California
Alta Bates Summit Medical Center-Herrick Campus
Berkeley, California
Providence Saint Joseph Medical Center/Disney Family Cancer Center
Burbank, California
Sutter Cancer Centers Radiation Oncology Services-Cameron Park
Cameron Park, California
Mercy San Juan Medical Center
Carmichael, California
Enloe Medical Center
Chico, California
21st Century Oncology - El Segundo
El Segundo, California
Fresno Cancer Center
Fresno, California
Saint Agnes Medical Center
Fresno, California
Marin General Hospital
Greenbrae, California
Veterans Administration Long Beach Medical Center
Long Beach, California
Los Angeles County-USC Medical Center
Los Angeles, California
USC / Norris Comprehensive Cancer Center
Los Angeles, California
Memorial Medical Center
Modesto, California
Kaiser Permanente Oakland-Broadway
Oakland, California
Kaiser Permanente-Oakland
Oakland, California
Desert Regional Medical Center
Palm Springs, California
Stanford Cancer Institute
Palo Alto, California
Feather River Cancer Center
Paradise, California
Pomona Valley Hospital Medical Center
Pomona, California
Kaiser Permanente-Rancho Cordova Cancer Center
Rancho Cardova, California
Kaiser Permanente-Redwood City
Redwood City, California
Kaiser Permanente-Richmond
Richmond, California
Rohnert Park Cancer Center
Rohnert Park, California
Kaiser Permanente-Roseville
Roseville, California
Sutter Cancer Centers Radiation Oncology Services-Roseville
Roseville, California
The Permanente Medical Group-Roseville Radiation Oncology
Roseville, California
Sutter General Hospital
Sacramento, California
University of California Davis Comprehensive Cancer Center
Sacramento, California
Mercy General Hospital Radiation Oncology Center
Sacramento, California
Kaiser Permanente-South Sacramento
Sacramento, California
Showing 40 of 518 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.